[go: up one dir, main page]

AU2001277524A1 - Novel use of inhibitors of the epidermal growth factor receptor - Google Patents

Novel use of inhibitors of the epidermal growth factor receptor

Info

Publication number
AU2001277524A1
AU2001277524A1 AU2001277524A AU7752401A AU2001277524A1 AU 2001277524 A1 AU2001277524 A1 AU 2001277524A1 AU 2001277524 A AU2001277524 A AU 2001277524A AU 7752401 A AU7752401 A AU 7752401A AU 2001277524 A1 AU2001277524 A1 AU 2001277524A1
Authority
AU
Australia
Prior art keywords
inhibitors
growth factor
factor receptor
epidermal growth
novel use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277524A
Inventor
Axel Behrens
Alexander Fleischmann
Thomas Metz
Maria Sibilia
Erwin Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2001277524A1 publication Critical patent/AU2001277524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001277524A 2000-07-06 2001-07-04 Novel use of inhibitors of the epidermal growth factor receptor Abandoned AU2001277524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00114482 2000-07-06
EP00114482A EP1170011A1 (en) 2000-07-06 2000-07-06 Novel use of inhibitors of the epidermal growth factor receptor
PCT/EP2001/007642 WO2002002120A1 (en) 2000-07-06 2001-07-04 Novel use of inhibitors of the epidermal growth factor receptor

Publications (1)

Publication Number Publication Date
AU2001277524A1 true AU2001277524A1 (en) 2002-01-14

Family

ID=8169176

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277524A Abandoned AU2001277524A1 (en) 2000-07-06 2001-07-04 Novel use of inhibitors of the epidermal growth factor receptor

Country Status (4)

Country Link
US (1) US20020102685A1 (en)
EP (1) EP1170011A1 (en)
AU (1) AU2001277524A1 (en)
WO (1) WO2002002120A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
IL159225A0 (en) 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EP1300146A1 (en) * 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
DE10154540A1 (en) * 2001-11-07 2003-05-22 Cellcontrol Biomedical Lab Ag Procedure for predicting or predicting the effectiveness of tumor treatment
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US8017321B2 (en) * 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
EP1751309B1 (en) 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
ES2564127T5 (en) * 2004-06-04 2020-03-26 Genentech Inc EGFR mutations
WO2006017317A2 (en) * 2004-07-12 2006-02-16 The General Hospital Corporation Method for the treatment of disease
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
KR20080003334A (en) * 2005-03-11 2008-01-07 더 리젠트스 오브 더 유니버시티 오브 콜로라도 Histone deacetylase inhibitors that sensitize cancer cells to epidermal growth factor inhibitors
ES2398709T5 (en) * 2005-06-28 2017-04-18 Genentech, Inc. Mutations in EGFR and KRAS to predict a patient's response to treatment with EGFR inhibitors
ATE477395T1 (en) 2006-06-09 2010-08-15 Univ Aberdeen RESONANCE ENHANCED DRILLING, METHOD AND APPARATUS
EP2099443A4 (en) * 2006-11-10 2010-05-05 Syndax Pharmaceuticals Inc Combination of er + ligands and histone deacetylase inhibitors for the treatment of cancer
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JP3088018B2 (en) * 1995-03-30 2000-09-18 ファイザー・インコーポレーテッド Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA001428B1 (en) * 1995-07-06 2001-02-26 Новартис Аг Pyrrolopyrimidines and pharmaceutical compositions
DE19608588A1 (en) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation
GB9608180D0 (en) * 1996-04-19 1996-06-26 Cancer Res Campaign Tech Phosphate analogues
IL143089A0 (en) * 1998-11-19 2002-04-21 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
JP4090200B2 (en) * 1999-02-11 2008-05-28 ファイザー・プロダクツ・インク Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer drugs

Also Published As

Publication number Publication date
WO2002002120A1 (en) 2002-01-10
US20020102685A1 (en) 2002-08-01
EP1170011A1 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2001237041A1 (en) Kinase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU6421101A (en) Surgical clip
AU2001229712A1 (en) Reduction of hair growth
AU2001234128A1 (en) Novel imidazoline compounds
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2001277524A1 (en) Novel use of inhibitors of the epidermal growth factor receptor
AU4431000A (en) Novel use
AU2002224808A1 (en) Use of thienopyrimidines
AU2002217071A1 (en) Novel use of polyhydroxy compounds
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2001239246A1 (en) Novel use of herbicides
AU3235100A (en) Prothease inhibitors
AU2001249074A1 (en) Human hepatocyte growth factor activator inhibitor homologue
AU7445100A (en) Sebum production inhibitors
AU5587200A (en) Synthesis of substituted amidines
AU3595900A (en) Tyrosine alkoxyguanidines as integrin inhibitors
AU4450100A (en) 225Ac-heha and related compounds, methods of synthesis and methods of use
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU2001240150A1 (en) Quinazoline synthesis
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors